FEIBA® NF

FEIBA® NF

FDA INDICATION: Control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and hemophilia B patients with inhibitors. Clinical experience suggests that patients with factor VIII inhibitor titer of less than 5 BU may be successfully treated with antihemophilic factor. Patients with titers ranging between 5 and 10 BU may either be treated with antihemophilic factor or FEIBA NF. Cases with factor VIII inhibitor titers greater than 10 BU have generally been refractory to treatment with antihemophilic factor. Package Insert

CLASS: Plasma-Derived

DISTRIBUTOR: Shire

VIAL SIZE: 500, 1000, 2500 Units

DILUENT SIZE: 20 mL or 50 mL

MIXING DEVICE: BAXJECT® II

ROOM TEMPERATURE STORAGE: Until product expiration

DURATION OF BYPASS ACTIVITY: 8–12 hours

OTHER WEBSITES: bleedingdisorders.comfeiba.com